Stock Scorer

AbCellera Biologics Inc. (ABCL)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. Every figure as a table ›

Revenue Quarterly

0 150M 300M 450M Q3 '21: 5.5M Q4 '21: 139.3M Q1 '22: 316.6M Q2 '22: 45.9M Q3 '22: 101.4M Q4 '22: 21.5M Q1 '23: 12.2M Q2 '23: 10.1M Q3 '23: 6.6M Q4 '23: 9.2M Q1 '24: 10M Q2 '24: 7.3M Q3 '24: 6.5M Q4 '24: 5M Q1 '25: 4.2M Q2 '25: 17.1M Q3 '25: 9M Q4 '25: 44.9M Q1 '26: 8.3M Q2 '26: 4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income Quarterly

-160M -80M 0 80M 160M 240M Q3 '21: -28.1M Q4 '21: 81.6M Q1 '22: 224.9M Q2 '22: -8.4M Q3 '22: 37.7M Q4 '22: -37.8M Q1 '23: -64.9M Q2 '23: -51.4M Q3 '23: -54.9M Q4 '23: -66.1M Q1 '24: -54.9M Q2 '24: -93.5M Q3 '24: -93.7M Q4 '24: -72.8M Q1 '25: -62.7M Q2 '25: -49.6M Q3 '25: -76.3M Q4 '25: -28.6M Q1 '26: -57.5M Q2 '26: -62.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-60M 0 60M 120M 180M Q3 '21: -21.4M Q4 '21: 59.9M Q1 '22: 168.6M Q2 '22: -6.8M Q3 '22: 26.6M Q4 '22: -29.9M Q1 '23: -40.1M Q2 '23: -30.5M Q3 '23: -28.6M Q4 '23: -47.1M Q1 '24: -40.6M Q2 '24: -36.9M Q3 '24: -51.1M Q4 '24: -34.2M Q1 '25: -45.6M Q2 '25: -34.7M Q3 '25: -57.1M Q4 '25: -8.9M Q1 '26: -43.2M Q2 '26: -55.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-200M -100M 0 100M 200M 300M Q3 '21: -5.9M Q4 '21: -16.7M Q1 '22: 100.2M Q2 '22: 273M Q3 '22: -126.8M Q4 '22: 30.9M Q1 '23: -44.1M Q2 '23: 19.9M Q3 '23: -106K Q4 '23: -19.6M Q1 '24: -41.7M Q2 '24: -30M Q3 '24: -28.9M Q4 '24: -8M Q1 '25: -11.6M Q2 '25: -32.4M Q3 '25: -52.6M Q4 '25: -34.7M Q1 '26: -33.5M Q2 '26: 25.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-180M -90M 0 90M 180M 270M Q3 '21: -14.5M Q4 '21: -26.1M Q1 '22: 85.7M Q2 '22: 241.7M Q3 '22: -139.3M Q4 '22: 18.6M Q1 '23: -59M Q2 '23: -7.3M Q3 '23: -20.4M Q4 '23: -34M Q1 '24: -65.8M Q2 '24: -50.1M Q3 '24: -47.4M Q4 '24: -23.6M Q1 '25: -22.2M Q2 '25: -45.8M Q3 '25: -61.5M Q4 '25: -44.6M Q1 '26: -37.4M Q2 '26: 23.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 150M 300M 450M Q1 '20: 151.9M Q2 '20: 260.8M Q3 '20: 153M Q1 '21: 320.3M Q2 '21: 272.2M Q3 '21: 278.9M Q1 '22: 311.5M Q2 '22: 284.7M Q3 '22: 315.8M Q1 '23: 287.8M Q2 '23: 288.9M Q3 '23: 289.5M Q1 '24: 292.7M Q2 '24: 294.2M Q3 '24: 294.9M Q1 '25: 297.7M Q2 '25: 298.5M Q3 '25: 298.9M Q1 '26: 303.1M Q2 '26: 305.6M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.90 -0.60 -0.30 0.00 0.30 0.60 0.90 Q3 '21: 0.72 Q4 '21: 0.47 Q1 '22: 0.64 Q2 '22: 0.63 Q3 '22: 0.79 Q4 '22: 0.50 Q1 '23: -0.18 Q2 '23: -0.27 Q3 '23: -0.45 Q4 '23: -0.52 Q1 '24: -0.52 Q2 '24: -0.54 Q3 '24: -0.61 Q4 '24: -0.55 Q1 '25: -0.56 Q2 '25: -0.55 Q3 '25: -0.57 Q4 '25: -0.49 Q1 '26: -0.48 Q2 '26: -0.54 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for ABCL: Gross Profit, Cost of Revenue. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.